A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Histologically Confirmed Nonalcoholic Steatohepatit
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
NGM Biopharmaceuticals
Start Date
May 1, 2015
End Date
October 31, 2019
Administered By
Medicine, Gastroenterology
Awarded By
NGM Biopharmaceuticals
Start Date
May 1, 2015
End Date
October 31, 2019